Latest Pharmaceuticals policy Stories
WASHINGTON, May 13, 2013 /PRNewswire-USNewswire/ -- Today, the United States government brought to a conclusion an eight-year criminal and civil investigation of Ranbaxy Laboratories Limited, India's largest generic drug company, and Ranbaxy, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy Laboratories, Inc., Ranbaxy USA, Inc., and Ohm Laboratories, Inc. ("Ranbaxy"). Ranbaxy has agreed to pay $500 million to resolve allegations of falsifying drug data and systemic manufacturing...
DUBLIN, Ohio, May 13, 2013 /PRNewswire/ -- The nation's fastest growing drug epidemic is not on the streets - it's in our medicine cabinets. (Photo: http://photos.prnewswire.com/prnh/20130513/CL11987-INFO) Prescription drug abuse and misuse is an epidemic in our country. A new infographic created by the Cardinal Health Foundation and The Ohio State University College of Pharmacy illustrates this issue and how we can all help by taking the GenerationRx Challenge. Some key...
LONDON and WILMINGTON, N.C., May 13, 2013 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announces the appointments of Dr Manuela Niewel and Lisa Bull to secure Chiltern's continued success and future growth. Dr Manuela Niewel has been appointed Medical Director to serve as therapeutic expert in the oncology area in the medical department. Manuela is a medical oncologist with more than 20 years experience in clinical research...
Instead of being more efficient, private insurers have cost Medicare almost $300 billion more over the life of the program A study published online today finds that the private insurance companies that participate in Medicare under the Medicare Advantage program and its predecessors have cost the publicly funded program for the elderly and disabled an extra $282.6 billion since 1985, most of it over the past eight years. In 2012 alone, private insurers were overpaid $34.1 billion....
PARSIPPANY, N.J., May 13, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for a progestin-only transdermal contraceptive patch (Norethindrone Transdermal Delivery System) for use by women to prevent pregnancy. The acceptance of the NDA for filing means FDA has determined that the application is sufficiently complete to permit a substantive review. The...
Drafted with assistance of Health Care Without Harm and Physicians for Social Responsibility, the resolution is intended to protect public health. San Francisco, CA (PRWEB) May 10, 2013 The University of California, San Francisco’s (UCSF) Academic Senate Coordinating Committee, the School of Pharmacy Faculty Council, and the School of Medicine Faculty Council unanimously approved a resolution in April to phase out the procurement of meat and poultry raised with non-therapeutic...
Brett Smith for redOrbit.com – Your Universe Online A groundbreaking study from a well-renowned team of Danish researchers could bring unprecedented relief for sufferers of chronic back pain. According to the study, which appeared in the European Spine Journal, as much as 40 percent of chronic lower back pain is caused by bacteria. Treating these patients with antibiotics has resulted in a significant amount of relief and increased quality of life when compared to those patients...
"The market is potentially huge... rising to $5 billion by 2018" HOLLYWOOD, Calif., May 10, 2013 /PRNewswire/ -- Medbox, Inc. (OTC Markets: MDBX) (www.medboxinc.com), a leader in providing consulting services and patented systems to the medical and retail industries, announced today that their company has been featured in an article in Bloomberg Businessweek. The report profiled the company, the management team, and the company's core product. "The devices sit behind sales counters...
TAINAN, Taiwan, May 10, 2013 /PRNewswire/ -- ScinoPharm Taiwan Ltd. (TSE: 1789.TW) and Coland Holdings Ltd. (TSE: 4144.TW) announced today that they have formed a strategic alliance to develop a series of generic oncological drugs for Mainland China. Several Active Pharmaceutical Ingredients (APIs) have been initially selected for development and future sales as injectable formulation products from the list of ScinoPharm-developed APIs. This will allow the companies to compete within...
Zontec developed this SPC software package for companies in the food, healthcare, pharmaceutical, medical device and other industries to meet FDA 21 CFR Part 11 and other regulations. Cincinnati, Ohio (PRWEB) May 08, 2013 Zontec Inc. the international developer of Statistical Process Control (SPC) software solutions, today announced a new Synergy SPC software validation service to its customers. “This package will be invaluable to our customers and prospects regulated by the Food and...
